短腸症候群の小児患者におけるテドゥグルチドの長期使用に関する症例報告
Tsuyoshi Sakurai1, Hironori Kudo1, Nakamura Megumi1
1Department of Pediatric Surgery, Tohoku University Hospital, Sendai, Japan.
まとめ
短腸症候群 (SBS) の小児患者が6年間にわたるテドゥグルチド (TED) 治療により,親腸栄養 (PN) から完全に独立することができました. この長期的ケーススタディはTEDが
科学分野:
- 小児胃腸内科
- 臨床事例研究
- 薬理学について
背景:
- 短腸症候群 (SBS) は腸不全の主な原因であり,しばしば長期の親腸栄養 (PN) を必要とする.
- グルカゴンのようなペプチド-2 アナログであるテドゥグルチド (TED) は,小児SBS患者におけるPN依存症の軽減に有望であることが示されています.
- 小児の集団におけるTEDの長期的な有効性に関するデータは限られている.
研究 の 目的:
- 短腸症候群 (SBS) を患った小児患者の長期Teduglutide (TED) 治療の事例を紹介する.
- 小児のSBS症例における親腸栄養 (PN) の独立性におけるTEDの持続的有効性と安全性を評価する.
主な方法:
- 小腸切除後のSBSの男性小児患者は5年間自宅でPNを受けていました.
- 5歳の時にTED臨床試験に参加し 承認後も治療を続けました
- 治療には6年以上のTED投与,PN量,カロリー摂取量,成長,栄養状態のモニタリングが含まれていました.
主要な成果:
- 6年以上のTED治療で,PN量とカロリー摂取量の徐々に持続した減少が観察されました.
- 患者はPNから完全に離乳し,成長と栄養状態が安定した.
- 治療期間中,TEDに関連する重度の有害事象は報告されていません.
結論:
- 小児短腸症候群 (SBS) の患者では,長期間Teduglutide (TED) を投与すると,親腸栄養 (PN) の独立性を含む好ましい結果が得られます.
- この事例は 腸の適応を長期にわたって 支援するTEDの可能性を 強調しています
- 重度の小児性SBSの管理には 個別化された長期的な治療戦略が不可欠です
関連する概念動画
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
282
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
282
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236


